NASDAQ: ALMSAlumis Inc Stock
$23.41+0.36 (+1.56%)
Updated Jun 18, 2026
ALMS Price
$23.41
Fair Value Price
$0.47
Market Cap
$2.98B
52 Week Low
$2.76
52 Week High
$30.60
P/E
-11.94x
P/B
5.26x
P/S
327.88x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.40M
Earnings
-$237.42M
Gross Margin
100%
Operating Margin
-2,927.59%
Profit Margin
-2,825.7%
Debt to Equity
0.18
Operating Cash Flow
-$376M
Beta
0.86
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ALMS Overview
Alumis Inc. is a biopharmaceutical firm currently in the clinical trial phase, dedicated to advancing and marketing therapeutic solutions for a range of autoimmune conditions. Its pipeline includes ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor, which is being investigated for its potential in addressing plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Another key candidate is A-005, also an allosteric TYK2 inhibitor, specifically designed to penetrate the central nervous system to target neuroinflammatory and neurodegenerative disorders. Originally established as Esker Therapeutics, Inc., the organization rebranded as Alumis Inc. in January 2022. Founded in 2021, Alumis maintains its corporate headquarters in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALMS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALMS
Ranked#323 of 465
Ranked#323 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important ALMS news, forecast changes, insider trades & much more!
ALMS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALMS ($23.41) is overvalued by 4,926.97% relative to our estimate of its Fair Value price of $0.47 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALMS ($23.41) is not significantly undervalued (4,926.97%) relative to our estimate of its Fair Value price of $0.47 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALMS due diligence checks available for Premium users.
Valuation
ALMS fair value
Fair Value of ALMS stock based on Discounted Cash Flow (DCF)
Price
$23.41
Fair Value
$0.47
Overvalued by
4,926.97%
ALMS ($23.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALMS ($23.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.94x
Industry
15.77x
Market
9.47x
ALMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.26x
Industry
4.95x
ALMS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALMS's financial health
Profit margin
Revenue
$1.7M
Net Income
-$93.1M
Profit Margin
-5,344.8%
ALMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALMS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$671.6M
Liabilities
$104.6M
Debt to equity
0.18
ALMS's short-term assets ($532.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALMS's short-term assets ($532.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$87.1M
Investing
-$285.7M
Financing
$347.0M
ALMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALMS vs Biotech Stocks
Alumis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.